Michael Torgov

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations

Pharmacy, Medicinal Chemistry, Oncology +14

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

Laura R. Saunders, Alexander J. Bankovich, Wade Anderson et al. · Science Translational Medicine · 2015 · 578 citations

Medicine, Oncology, Pharmacology +17

Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides

Michael Sun, Kevin S. Beam, Charles G. Cerveny et al. · Bioconjugate Chemistry · 2005 · 365 citations · Full text

Pharmacy, Biochemistry, Pharmacology +17

Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97

Leia M. Smith, Albina Nesterova, Stephen C. Alley et al. · Molecular Cancer Therapeutics · 2006 · 100 citations

Medicine, Oncology, Pharmacology +15

Design, Synthesis, and in Vitro Evaluation of Dipeptide-Based Antibody Minor Groove Binder Conjugates

Scott C. Jeffrey, Michael Torgov, Jamie B. Andreyka et al. · Journal of Medicinal Chemistry · 2005 · 90 citations

Pharmacy, Pharmaceutics, Pharmacology +17